Johannes Bischof, PhD provides exciting insights into the field of gene therapy research using CRISPR

The results of a new study from EB-Haus Austria are promising. For the first time, COL17A1 correction by gene editing in JEB was successful. The used method (Cas9 nickase-based gene editing) showed great potential in the restoration of collagen production. The efficacy was proven with several methods on protein as well as genomic level (e.g. Western blot, immunofluorescence, PCR).
In this interview, Johannes Bischof, PhD talks about the extent to which the findings could also be useful for clinical approaches and the challenges that need to be overcome in the future.

The interview on the study with Johannes Bischof, PhD can be accessed here